{"id":"W3023737799","doi":"10.1016/j.parkreldis.2020.04.012","title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study","year":2020,"lang":"en","type":"article","venue":"Parkinsonism & Related Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi K.K.; Bayer Yakuhin; Novartis Pharma; Ono Pharmaceutical; Eisai Canada; Mitsubishi Tanabe Pharma Corporation; Kao Corporation; Otsuka Pharmaceutical; Daiwa Securities Health Foundation; Sanofi; Kyowa Hakko Kirin; Boston Scientific Japan; Eisai; Daiichi-Sankyo; Ohara Pharmaceuticals; Kissei; Mylan; Ehime University; Boehringer Ingelheim Japan; Nihon Pharmaceutical; Alexion Pharmaceuticals; Nihon Medi-Physics; Takeda Pharmaceutical Company; Daiichi Sankyo Company; Meiji Seika Pharma; Dainippon Sumitomo Pharma; Novartis Pharmaceuticals Corporation; Kagoshima University; Medtronic; Asahi Kasei Pharma Corporation","keywords":"Parkinson's disease; Placebo; Double blind; Medicine; Disease; Physical therapy; Internal medicine; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002467724,0.00160065,0.003444894,0.0005971103,0.0005050455,0.0009792118,0.001098287,0.001984099,0.004246411],"category_scores_gemma":[0.001705774,0.0008608064,0.002484796,0.0004513343,0.001372979,0.0008893272,0.0003409406,0.002493961,0.0007505882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006453042,"about_ca_system_score_gemma":0.001398178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006941573,"about_ca_topic_score_gemma":0.00172967,"domain_scores_codex":[0.9992121,0.0004114462,0.00006980362,0.0001191959,0.00009055046,0.00009688352],"domain_scores_gemma":[0.9984704,0.0004369048,0.0003082311,0.0001240042,0.0001426226,0.0005178762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9631057,0.01715478,0.0007306646,0.0004984116,0.0006635849,0.00005239611,0.00005529906,0.0001398832,0.005026458,0.0000299904,0.0002683503,0.01227457],"study_design_scores_gemma":[0.8891188,0.1081091,0.001671371,0.0000169327,0.0003372856,0.00002072839,0.00001160114,0.00016652,0.0003531678,0.00002398989,0.0001616862,0.0000088129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925309,0.002834226,0.0004039961,0.0002596739,0.0002506991,0.002417395,0.0005009483,0.00006235782,0.0007398169],"genre_scores_gemma":[0.9894094,0.002822299,0.001458278,0.0008052909,0.000465017,0.002962463,0.0007911693,0.00002023937,0.001265681],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004246411,"threshold_uncertainty_score":0.01420569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01491475238957364,"score_gpt":0.2872012289221813,"score_spread":0.2722864765326076,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}